Saxenda vs Wegovy
Which Is Right for You? Complete Comparison (2026)
Saxenda (liraglutide) vs Wegovy (semaglutide): compare weight loss results, side effects, dosing frequency, and who should switch. Full 2026 comparison.
Saxenda vs Wegovy: At a Glance
- ✓First-generation daily GLP-1 receptor agonist
- ✓FDA-approved for T2D (Victoza 1.8 mg) and obesity (Saxenda 3.0 mg)
- ✓~8% mean weight loss at 56 weeks (SCALE, 3.0 mg)
- ✓Positive cardiovascular outcome data (LEADER trial)
- ✓Requires daily injection (vs weekly for semaglutide)
- ✓Targets GLP-1 receptors only — single incretin agonist
- ✓Suppresses appetite via hypothalamic action
- ✓Slows gastric emptying — prolongs satiety
- ✓~15% mean weight loss at 68 weeks (STEP-1, 2.4 mg)
- ✓Half-life ~7 days — once-weekly injection
Detailed Comparison
| Feature | Saxenda | Wegovy |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1 receptor agonistBest |
| Dosing | 0.6-3.0 mg SC daily | 0.25-2.4 mg SC weekly (weight loss); 3-14 mg oral daily |
| Administration | Subcutaneous injection daily | Subcutaneous injection weekly or oral daily |
| Half-life | ~13 hours — requires daily dosing | ~7 days |
| FDA Status | FDA-approved: Victoza (T2D), Saxenda (obesity) | FDA-approved: Ozempic (T2D), Wegovy (obesity), Rybelsus (oral, T2D) |
| Key Trial | Pi-Sunyer X et al. NEJM 2015 (SCALE) — 8% weight loss | Wilding JPH et al. NEJM 2021 (STEP-1) — 14.9% weight loss |
| Side Effects | Nausea, vomiting, diarrhea — similar to semaglutide | Nausea (44%), vomiting, diarrhea, constipation |
Which Should You Choose?
Liraglutide (glp-1 receptor agonist) and Semaglutide (glp-1 receptor agonist) serve different clinical roles despite both being in the GLP-1 agonist space. Liraglutide first-generation long-acting glp-1 receptor agonist with daily dosing. Semaglutide long-acting glp-1 receptor agonist that suppresses appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Saxenda vs Wegovy: Frequently Asked Questions
Liraglutide is a glp-1 receptor agonist while Semaglutide is a glp-1 receptor agonist. They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
Liraglutide works as a glp-1 receptor agonist (0.6-3.0 mg SC daily), while Semaglutide is a glp-1 receptor agonist (0.25-2.4 mg SC weekly (weight loss); 3-14 mg oral daily). They have different half-lives (~13 hours — requires daily dosing vs ~7 days), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Track Saxenda or Wegovy in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.
📚References & sources
Latest on Saxenda
Which GLP-1 Works Best? New Meta-Study Puts Medications Head-to-Head
A comprehensive meta-analysis from the University of Georgia compares three major GLP-1 medications. Discover which drug offers the highest weight loss efficacy and what the data means for patients.
8 min read
Zepbound vs. Wegovy: New Meta-Analysis Reveals Top Weight Loss Drug
A comprehensive meta-analysis from the University of Georgia has finally put major weight loss medications head-to-head. Here is what the data says about Zepbound, Wegovy, and Saxenda.
8 min read
Beyond Weight Loss: Do GLP-1 Drugs Impact Mental Health?
New research is exploring the surprising potential of GLP-1 receptor agonists, known for their role in diabetes and weight management, to also influence mental well-being. This article delves into the latest findings and what they mean for patients.
7 min read